Discovered by BIOTEC research team together with the Medicines for Malaria Venture (MMV), the patented P218 compound was designed based-on 3-dimensional structures of malaria protein target, dihydrofolate reductase, in order to circumvent mutations that had led to resistance to pyrimethamine, […]
Recent Posts
- Congratulations to " Dr. Kobkul Laoteng and Team" for winning 2nd Runner-Up in the Industrial Category at the 2025 Thai Rice Innovation Competition
10/03/2025 - BIOTEC Welcomes China’s Ministry of Foreign Affairs Delegation for Project Site Visit and Evaluation
09/26/2025 - BIOTEC Celebrates 42nd Anniversary of Biotechnology Innovation
09/25/2025